Mizuho lowered the firm’s price target on Nkarta (NKTX) to $16 from $20 and keeps an Outperform rating on the shares. The analyst updated models in the biotechnology group following the Q3 reports. The firm removed the potential contribution of NKX019 in large B-cell malignancies, upon Nkarta announcing that it will no longer further development in this indication.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NKTX:
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue